connective tissue growth factor ctgf  (Santa Cruz Biotechnology)

Journal: Renal Failure

Article Title: Lactate induces renal lipid accumulation and aggravates renal fibrosis by inhibiting the PPARα signaling pathway and fatty acid oxidation

doi: 10.1080/0886022X.2026.2630507

Figure Lengend Snippet: Impaired renal function and renal tissue fibrosis in UUO mice. (A − C) H&E staining and Masson staining in each group ( n = 6). Scale bar = 50 μm. (D and E) BUN and Scr levels in each group ( n = 6). (F − H) Protein expression levels of FN and CTGF in renal tissues ( n = 3). (I and J) mRNA expression levels of FN and CTGF in renal tissues ( n = 6). (K − M) Immunohistochemical staining and quantification for the expression levels of α-SMA and E-cad in renal tissues ( n = 3). Scale bar = 50 μm. ** p < 0.01 vs Sham, *** p < 0.001 vs Sham.

Article Snippet: Primary antibodies against α-smooth muscle actin (α-SMA, AF1032), fibronectin (FN, AF5335), connective tissue growth factor (CTGF, 15f5788), E-cadherin (E-cad, BF0219), peroxisome proliferator-activated receptor α (PPARα, AF5301), peroxisome proliferator-activated receptor gamma coactivator 1 alpha (PGC1α, AF5395), and sterol regulatory element-binding protein 1 (SREBP1, AF6283) were purchased from Affinity Biosciences (Wuhan, China).

Techniques: Staining, Expressing, Immunohistochemical staining

Journal: Scientific Reports

Article Title: Combination of THU/ALK-5i exhibits profound anti-MASH activity through suppression of lipogenesis and fibrogenesis

doi: 10.1038/s41598-025-23626-3

Figure Lengend Snippet: EW-7197 suppresses hepatic fibrosis in LX-2 cells. Cellular morphology after treatment ( A ). α-SMA staining ( B ). Expression of p-Smad3 and the downstream proteins (Col1A, α-SMA, and CTGF) in the canonical pathway ( C ). Representative bar graphs of p-Smad3 and its downstream profibrotic proteins ( D , E ). * p < 0.05, † p < 0.01 vs. CON group, ‡ p < 0.05, § p < 0.01 vs. TGF-β control group. Values are presented as the means ± SEM.

Article Snippet: The following antibodies were used: α-smooth muscle actin (α-SMA; SC-32251), collagen type I (Col1A; SC-293182), connective tissue growth factor (CTGF; SC-101586), sterol regulatory element-binding protein-1c (Srebp-1c; #SC-13551), fatty acid synthase (Fasn; SC-55580), monocyte chemoattractant protein-1 (MCP-1; SC-28879), interleukin-1β (IL-1β; SC-12742), and β-actin (SC-47778), which purchased from Santa Cruz Biotechnology (CA, USA).

Techniques: Staining, Expressing, Control

Journal: Scientific Reports

Article Title: Combination of THU/ALK-5i exhibits profound anti-MASH activity through suppression of lipogenesis and fibrogenesis

doi: 10.1038/s41598-025-23626-3

Figure Lengend Snippet: EW-7197 attenuates hepatocellular fibrosis with lipid metabolism derangement in hepatocytes. Cellular morphology after treatment ( A ). BODIPY staining ( B ). α-SMA staining ( C ). Expression of p-Smad3 and the downstream proteins (Col1A, α-SMA, and CTGF) in the canonical pathway ( D ). Representative bar graphs of p-Smad3 and its downstream profibrotic proteins ( E , F ). Lipid droplet count/cell ( G ). Lipid droplet area/cell ( H ). Lipid droplet intensity/cell ( I ). Protein levels of lipogenic genes; Srebp-1c and Fasn ( J ). Representative bar graphs of the lipogenic genes ( K ). * p < 0.05, † p < 0.01 vs. CON group, ‡ p < 0.05, § p < 0.01 vs. TGF-β control group, ŧ p < 0.05 vs. TGF-β plus EW group. px; pixels, a.u.; arbitrary units. Values are presented as the means ± SEM.

Article Snippet: The following antibodies were used: α-smooth muscle actin (α-SMA; SC-32251), collagen type I (Col1A; SC-293182), connective tissue growth factor (CTGF; SC-101586), sterol regulatory element-binding protein-1c (Srebp-1c; #SC-13551), fatty acid synthase (Fasn; SC-55580), monocyte chemoattractant protein-1 (MCP-1; SC-28879), interleukin-1β (IL-1β; SC-12742), and β-actin (SC-47778), which purchased from Santa Cruz Biotechnology (CA, USA).

Techniques: Staining, Expressing, Control